安罗替尼联合吉非替尼治疗EGFR突变NSCLC导致严重皮下出血1例
|
摘要
安罗替尼为我国自主研发的新型小分子多靶点酪氨酸激酶抑制剂,可强效抑制多个靶点,因其显著延长总生存期(OS)及无进展生存期(PFS)而受到瞩目,不良反应主要包括高血压和蛋白尿,偶有致死性咯血报道。本文报道了安罗替尼联合吉非替尼治疗EGFR突变晚期非小细胞肺癌(NSCLC)导致严重皮下出血1例,为临床预防安罗替尼的不良反应提供参考。
Anlotinib is a novel small-molecule multi-target tyrosine kinase inhibitor which is independently developed in China. It can effectively inhibit multiple targets. And it is attracting attention for its significant prolongation of OS and PFS. Its adverse reactions mainly include high blood pressure and proteinuria, and there are occasional reports of lethal hemoptysis. In this article, we reported a case of severe subcutaneous hemorrhage caused by anlotinib plus gefitinib treatment for advanced NSCLC patient with EGFR mutations, so as to provide a reference for clinical prevention of adverse effects of anlotinib.
Anlotinib is a novel small-molecule multi-target tyrosine kinase inhibitor which is independently developed in China. It can effectively inhibit multiple targets. And it is attracting attention for its significant prolongation of OS and PFS. Its adverse reactions mainly include high blood pressure and proteinuria, and there are occasional reports of lethal hemoptysis. In this article, we reported a case of severe subcutaneous hemorrhage caused by anlotinib plus gefitinib treatment for advanced NSCLC patient with EGFR mutations, so as to provide a reference for clinical prevention of adverse effects of anlotinib.
引文
[1]Ettinger DS, Wood DE, Aisner DL, et al. Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology[J]. J Natl Compr Canc Netw, 2017,15(4):504-535. doi:10.6004/jnccn.2017.0050.
[2]Han BH, Li K, Wang QM, et al. Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer[J].JAMA Oncology, 2018. doi:10.1001/jamaoncol.2018.3039.
[3]严丹芳,严森祥,杨劲松,等.口服易瑞莎致非小细胞肺癌颅内出血事件3例报道及文献复习[C].浙江省放射肿瘤治疗学学术年会, 2009.
[4]吴军,王婧,曹邦伟.抗肿瘤血管生成药物不良反应的发生机制及处理[J].医学综述, 2016, 22(16):3154-3157.doi:10.3969/j. issn.1006-2084.2016.16.010.
[5]邹文,李晓梅,王荣梅.阿帕替尼联合应用替吉奥致严重皮下出血及皮肤破溃1例[J].中国新药与临床杂志, 2017,36(03):176-179. doi:CNKI:SUN:XYYL.0.2017-03-012.
[6]Elice F, Rodeghiero F. Side effects of anti-angiogenic drugs[J]. Thromb Res, 2012, 129 Suppl 1:S50-53. doi:10.1016/S0049-3848(12)70016-6.
[2]Han BH, Li K, Wang QM, et al. Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer[J].JAMA Oncology, 2018. doi:10.1001/jamaoncol.2018.3039.
[3]严丹芳,严森祥,杨劲松,等.口服易瑞莎致非小细胞肺癌颅内出血事件3例报道及文献复习[C].浙江省放射肿瘤治疗学学术年会, 2009.
[4]吴军,王婧,曹邦伟.抗肿瘤血管生成药物不良反应的发生机制及处理[J].医学综述, 2016, 22(16):3154-3157.doi:10.3969/j. issn.1006-2084.2016.16.010.
[5]邹文,李晓梅,王荣梅.阿帕替尼联合应用替吉奥致严重皮下出血及皮肤破溃1例[J].中国新药与临床杂志, 2017,36(03):176-179. doi:CNKI:SUN:XYYL.0.2017-03-012.
[6]Elice F, Rodeghiero F. Side effects of anti-angiogenic drugs[J]. Thromb Res, 2012, 129 Suppl 1:S50-53. doi:10.1016/S0049-3848(12)70016-6.